scholarly journals Carbonyl iron therapy for iron deficiency anemia

Blood ◽  
1986 ◽  
Vol 67 (3) ◽  
pp. 745-752 ◽  
Author(s):  
VR Gordeuk ◽  
GM Brittenham ◽  
CE McLaren ◽  
MA Hughes ◽  
LJ Keating
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Carbonyl Iron ◽  
Deficiency Anemia ◽  
Iron Salts ◽  
Gastrointestinal Side Effects ◽  
Iron Poisoning ◽  
Poisoning In Children ◽  
Donated Blood

Abstract To determine if elemental carbonyl iron powder is safe and effective therapy for iron deficiency anemia, 20 nonanemic and 32 anemic volunteers were studied. Single doses of 1,000 to 10,000 mg of carbonyl iron (15 to 150 times the 65 mg of iron in the usual dose of ferrous sulfate) were tolerated by nonanemic volunteers with no evidence of toxicity and only minor gastrointestinal side effects. Anemic volunteers (menstruating women who had previously donated blood) were treated with several regimens providing 1,000 to 3,000 mg of carbonyl iron daily in one to three doses for 8 to 28 days. After 12 weeks anemia was corrected in 29 of 32 patients, and serum ferritin was greater than 12 micrograms/L in 14. Hemoglobin regeneration proceeded at a rate similar to that described for therapy with oral iron salts and parenteral iron dextran. There was no evidence of hematologic, hepatic, or renal toxicity, but mild gastrointestinal side effects occurred in a majority of anemic volunteers. Carbonyl iron is an effective, inexpensive treatment for iron deficiency anemia, is accompanied by tolerable side effects and may have an advantage over therapy with iron salts by substantially reducing or eliminating the risk of iron poisoning in children.

scholarly journals Carbonyl iron therapy for iron deficiency anemia

Blood ◽  
1986 ◽  
Vol 67 (3) ◽  
pp. 745-752
Author(s):  
VR Gordeuk ◽  
GM Brittenham ◽  
CE McLaren ◽  
MA Hughes ◽  
LJ Keating
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Carbonyl Iron ◽  
Deficiency Anemia ◽  
Iron Salts ◽  
Gastrointestinal Side Effects ◽  
Iron Poisoning ◽  
Poisoning In Children ◽  
Donated Blood

To determine if elemental carbonyl iron powder is safe and effective therapy for iron deficiency anemia, 20 nonanemic and 32 anemic volunteers were studied. Single doses of 1,000 to 10,000 mg of carbonyl iron (15 to 150 times the 65 mg of iron in the usual dose of ferrous sulfate) were tolerated by nonanemic volunteers with no evidence of toxicity and only minor gastrointestinal side effects. Anemic volunteers (menstruating women who had previously donated blood) were treated with several regimens providing 1,000 to 3,000 mg of carbonyl iron daily in one to three doses for 8 to 28 days. After 12 weeks anemia was corrected in 29 of 32 patients, and serum ferritin was greater than 12 micrograms/L in 14. Hemoglobin regeneration proceeded at a rate similar to that described for therapy with oral iron salts and parenteral iron dextran. There was no evidence of hematologic, hepatic, or renal toxicity, but mild gastrointestinal side effects occurred in a majority of anemic volunteers. Carbonyl iron is an effective, inexpensive treatment for iron deficiency anemia, is accompanied by tolerable side effects and may have an advantage over therapy with iron salts by substantially reducing or eliminating the risk of iron poisoning in children.

scholarly journals Comparison of Conventional and Newer Iron Preparations for the Treatment of Iron Deficiency Anaemia in Children

2020 ◽  
Vol 24 (2) ◽  
pp. 112-116
Author(s):  
Asmat Perveen ◽  
Naima Fazil Raja ◽  
Imran Mahmood Khan ◽  
Hijab Shaheen ◽  
Muhammad Imran ◽  
...  
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Controlled Trial ◽  
Ferrous Sulphate ◽  
Study Groups ◽  
Deficiency Anemia ◽  
Systematic Sampling ◽  
Gastrointestinal Side Effects ◽  
Group 2

Introduction: Commonly used iron salt, ferrous sulphate for the treatment of iron deficiency anemia, has several gastrointestinal side effects. Nowadays new iron salts such as ferrous bisglycinate are marketed with claims of raising hemoglobin faster with fewer gastrointestinal side effects. Objective: To compare the efficacy of ferrous sulphate with ferrous bisglycinate for the treatment of iron deficiency anemia in children. Methods: This randomized controlled trial was carried out at Children Hospital, PIMS, Islamabad from July 2015 to June 2016. A total of 136 children were selected through systematic sampling and randomized into 2 groups using a computer-generated table of random numbers; ferrous sulphate as group 1 and ferrous bisglycinate as group 2. Clinical outcome was assessed on the basis of a mean increase in hemoglobin after 12 weeks of therapy in both groups. The data was entered and analyzed using SPSS version 20.   Results: The baseline characteristics i.e. mean age, mean hemoglobin levels were similar in both study groups. After 12 weeks of treatment, the mean increase in hemoglobin was 1.8  ±1.59 g/dl in ferrous sulphate group as compare to 2.5  ±1.31g/dl in ferrous bisglycinate group showing the higher level of rising with ferrous bisglycinate than ferrous sulphate, P =0.0033. Conclusion: Newer iron preparation, ferrous bisglycinate is a better treatment option than conventional preparation of ferrous sulphate for increasing hemoglobin in iron deficiency anemia in children.

scholarly journals Lactoferrin Efficacy versus Ferrous Sulfate in Treatment of Children with Iron Deficiency Anemia

2021 ◽  
Vol 11 (01) ◽  
pp. e199-e204
Author(s):  
Osama Mahmoud El-Asheer ◽  
Ahmed Gaber Ahmed ◽  
Zainab AbdelAal Abdel Hafez ◽  
Marwa AbdelHafiz Dahpy ◽  
Amal AbdElSalam Soliman
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Patient Compliance ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Serum Iron ◽  
Deficiency Anemia ◽  
Serum Transferrin ◽  
Iron Binding ◽  
Clinical Benefits

AbstractLactoferrin (LF) is an iron-binding globular glycoprotein that is structurally and chemically similar to serum transferrin. Many studies have been done to evaluate the effect of oral LF administration on iron deficiency anemia (IDA) with controversial results. This study was designed to compare the efficacy of LF versus oral ferrous sulfate (OFS) therapy in the treatment of children with IDA. A significant increase in mean hemoglobin and serum iron concentrations was noted in the group that received oral bovine LF (11.06 ± 0.96 and 42.79 ± 6.14, respectively) versus the group that received OFS (10.24 ± 0.57 and 28.94 ± 5.05, respectively, with p < 0.001 for each) after 30 days of the treatment with fewer side effects (9.3 vs. 33.3% with p = 0.043). Oral bovine LF is a more effective and safer alternative in treating iron deficiency and IDA compared with OFS with clinical benefits of fewer side effects and better patient compliance.

High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial

1987 ◽  
Vol 46 (6) ◽  
pp. 1029-1034 ◽  
Author(s):  
V R Gordeuk ◽  
G M Brittenham ◽  
M Hughes ◽  
L J Keating ◽  
J J Opplt
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Carbonyl Iron ◽  
Deficiency Anemia ◽  
High Dose ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial

scholarly journals Ferrous sulfate in the treatment of iron deficiency anemia: The positions continue

2017 ◽  
Vol 89 (10) ◽  
pp. 108-112
Author(s):  
L I Dvoretsky
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Dosage Form ◽  
Iron Sulfate ◽  
Deficiency Anemia ◽  
Iron Release ◽  
Comparative Efficacy ◽  
Peroxidation Processes

The paper discusses treatment strategy and tactics for iron deficiency anemia. It gives data on the comparative efficacy of different iron sulfate drugs, their bioavailability, effects on peroxidation processes, and side effects. The paper also considers the clinical significance of a dosage form of iron-containing drugs with a sustained iron release, as well as ways to reduce the frequency and magnitude of side effects when ferrous sulfate is used.

scholarly journals DARVYADILEHA: A DRUG REVIEW

2021 ◽  
Vol 9 (5) ◽  
pp. 70-78
Author(s):  
Patni Prachi ◽  
◽  
Singh Deepshikha ◽  
Garg G.P ◽  
◽  
...  
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Key Words ◽  
Iron Deficiency Anemia ◽  
Deficiency Anemia ◽  
Nutritional Anemia ◽  
Drug Review

Darvyadi Leha is a herbo-mineral compositionused in the treatment of Pandu Roga.Pandu Roga can be co-related with iron deficiency anemia (IDA) due to close clinical presentation.This formulation is mentioned in CharakSamhita under PanduRogaPrakran. As nutritional anemia has an immense prevalence all over Indiaand there are many side effects of oral allopathic iron preparations, thereforeAyurvedicherbo-mineral medications such as Darvyadi Leha can be a better alternative for the treatment of IDA.It is a safe and effective formulation with almost no adverse effects.This article reviews Ayurvedic properties of various ingredients of Dravyadi Leha and discusses how combination of all its ingredients makes the drug so effective.The articles were searched from various indexing sites including Scopus, PubMed, google scholar.The key words used were PanduRoga Iron Deficiency Anemia, Ayurveda.

A comparative study between the dispersible Ferric pyrophosphate particles and Ferrous sulfate in treatment of pediatric patients with iron deficiency anemia

2021 ◽  
Author(s):  
Fady M. El-Gendy ◽  
Ayat A El- Gendy ◽  
Mahmoud A. El-Hawy
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Complete Blood Count ◽  
Deficiency Anemia ◽  
P Value ◽  
Liquid Form ◽  
Ferric Pyrophosphate ◽  
Significant Difference

Background: Iron deficiency anemia (IDA) is the most common type of anemia related to malnutrition worldwide. It represents a major problem in developing countries, especially in Egypt. Ferric pyrophosphate (FPP) is a water-insoluble iron compound often used to fortify infant cereals and chocolate drink powders. It causes no adverse color and flavor changes to food vehicles. This study was done to compare the efficacy of FPP (micro dispersed iron) and ferrous sulfate (FS) in treating childhood IDA. Materials and Methods: This prospective cohort study was conducted on 58 anemic children visiting the outpatient clinic, pediatric department of Menoufia University hospitals from March 2017 to June 2019. The inclusion criteria of the involved children were age 2 - 12 years and the diagnosis of IDA. Patients with other types of anemia were excluded from the study. Verbal permission was obtained from the parents of the children according to the ethical committee of Menoufia University. Patients were randomly divided into 2 groups. Group1 included 29 children who were treated with FPP and group2 included 29 children who were treated with oral traditional iron in the form of FS. Complete blood count and iron profile were recorded before and after 8 weeks of treatment. Results: The results showed no statistically significant difference between the FPP group and the FS group regarding clinical examinations (P-value > 0.05). There was no significant difference regarding hemoglobin, serum iron, and serum ferritin between the FPP and the FS groups after treatment (P-value> 0.05). However, side effects were significantly higher in the FS group (P-value > 0.001). Conclusion: Micro dispersed iron could be used as an alternative therapy for children with IDA who refuse oral iron therapy in a liquid form with more tolerability and fewer side effects.

Sign in / Sign up

Export Citation Format

Share Document